The India BioEconomy Report (IBER) 2026

Context: Union Minister unveiled the India BioEconomy Report (IBER) 2026 during the 14th Foundation Day of BIRAC in New Delhi.

• The report highlights that India’s bioeconomy reached a record $195.3 billion in 2025, now contributing nearly 5% to the national GDP.

About The India BioEconomy Report (IBER) 2026:

What it is?

• The IBER 2026 is a comprehensive annual document developed by the Association of Biotechnology Led Enterprises (ABLE). It serves as the primary benchmark for measuring the growth, sectoral contributions, and startup ecosystem of India’s biotechnology sector, tracking the country’s progress toward its long-term economic goals.

Key Summary Points of the Report:

• Record Market Size: India’s BioEconomy grew by $29.6 billion in 2025 to reach a total of $195.3 billion.
• Highest Growth Rate: The sector witnessed an 18% growth in 2025, the highest rate recorded in recent years.
• GDP Contribution: The BioEconomy’s share of the national GDP rose to 4.8%, up from 4.2–4.3% in previous years.
• Sectoral Leader: The BioIndustrial segment was the largest contributor, valued at $90.2 billion.
• BioPharma Strength: This segment reached $64.5 billion, with significant growth expected in biosimilars and peptide manufacturing as global patents expire.
• BioServices and Agri: BioServices contributed $26 billion, while BioAgri accounted for $14.6 billion of the total economy.
• GCC Expansion: India now hosts over 150 healthcare and life sciences Global Capability Centres (GCCs), employing 300,000+ professionals.
• Startup Surge: The number of registered biotech startups rose to 11,855, with 1,780 new startups established in 2025 alone.

Key Opportunities in India’s Bioeconomy:

• Biosimilar and Peptide Manufacturing: Expiry of major drug patents (e.g., GLP-1 therapies) gives India a chance to produce affordable biosimilars and dominate global pharma markets.
• Global Capability Centres (GCCs) Expansion: India can move from backend roles to advanced R&D, bioinformatics, and digital health innovation, enhancing value addition and global leadership.
• BioIndustrial and BioServices Growth: Emerging sectors like bio-manufacturing and contract research are entering a scale-up phase, enabling large industrial applications and exports.
• Start-up Ecosystem Scaling: With ~12,000 biotech startups and steady growth, India can convert scientific research into market-ready products and deep-tech innovations.
• Domestic Market Contribution: Rising GDP share (~4.8%) offers scope to integrate biotechnology across agriculture, healthcare, and industry for holistic economic growth.

Initiatives Taken So Far:

• BIRAC Support: The Biotechnology Industry Research Assistance Council (BIRAC) provides the necessary interface to nurture and scale biotech startups.
• SIGHT Program: Financial incentives for green hydrogen and electrolyzer manufacturing to bolster the BioIndustrial segment.
• National Bio-Pharma Mission: An industry-academia collaborative mission for accelerating biopharmaceutical development.
• Bio-E3 Policy: (Biotechnology for Economy, Environment, and Employment) Focusing on high-performance biomanufacturing to achieve a $1 trillion target by 2047.

Challenges Associated:

• Intellectual Property (IP) Barriers: While GLP-1 patents are expiring, navigating complex biosimilar litigation remains a hurdle for Indian firms.
• Global Work Distribution: Multinational companies are distributing research across global networks, which can lead to brain drain if domestic high-end roles aren’t created.
• High Capital Intensity: Biotech startups require long-term funding; while 1,780 new ones launched in 2025, sustaining them through clinical trials is difficult.
• Regulatory Complexity: Expanding analytics and regulatory functions in GCCs requires a highly specialized workforce that keeps pace with changing global standards.
• Sectoral Imbalance: The BioAgri segment ($14.6B) is significantly smaller than the BioIndustrial segment ($90.2B), showing a lag in agricultural biotech adoption.

Way Ahead:

• Collaborative Ecosystem: Strengthen the Sustained collaboration between government, academia, and industry to translate lab research into market-ready technology.
• Biosimilar Leadership: Leverage the upcoming patent cliff to establish India as a global hub for peptide and biosimilar manufacturing.
• Expanding GCC Functions: Transition GCCs from support roles to core hubs for data analytics, bioinformatics, and digital health platforms.
• Incentivizing Startups: Provide targeted fiscal support to the nearly 12,000 registered startups to move beyond the establishment phase.
• Focus on 2047 Vision: Align all sectoral policies toward the long-term goal of building a $1 trillion BioEconomy by 2047.